Brookline Capital Management Predicts CRBU FY2026 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Analysts at Brookline Capital Management dropped their FY2026 earnings per share (EPS) estimates for Caribou Biosciences in a research note issued to investors on Monday, November 3rd. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($0.99) per share for the year, down from their previous forecast of ($0.97). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ FY2027 earnings at ($1.46) EPS, FY2028 earnings at ($2.09) EPS and FY2029 earnings at ($3.80) EPS.

Several other research firms also recently commented on CRBU. Citigroup boosted their target price on shares of Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, October 8th. Truist Financial set a $7.00 price target on Caribou Biosciences in a report on Tuesday. Wall Street Zen upgraded Caribou Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 24th. Finally, HC Wainwright upped their target price on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Caribou Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Caribou Biosciences Price Performance

NASDAQ:CRBU opened at $2.17 on Wednesday. The firm has a 50-day moving average of $2.20 and a 200-day moving average of $1.68. The company has a market cap of $202.08 million, a PE ratio of -1.22 and a beta of 2.59. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. The business had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%.

Hedge Funds Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Liberty Wealth Management LLC bought a new position in Caribou Biosciences during the third quarter valued at $45,000. Next Capital Management LLC bought a new position in Caribou Biosciences during the second quarter worth about $25,000. Creative Planning bought a new position in Caribou Biosciences during the second quarter worth about $25,000. Hudson Bay Capital Management LP bought a new position in Caribou Biosciences in the 2nd quarter worth approximately $30,000. Finally, Savant Capital LLC bought a new position in Caribou Biosciences in the 2nd quarter worth approximately $36,000. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.